Butylated Hydroxyanisole vs Potassium Bromate: which is worse?

What is Butylated Hydroxyanisole?

Butylated hydroxyanisole (BHA) is a synthetic phenolic antioxidant preservative derived from petroleum. It is a mixture of two isomeric compounds (2-BHA and 3-BHA). BHA prevents fats and oils from oxidizing (going rancid), extending shelf life. Its chemical formula is C11H16O2.

What is Potassium Bromate?

Potassium bromate (KBrO3) is an oxidizing agent used in commercial bread baking as a flour maturing agent and dough conditioner. It strengthens gluten networks, improves dough elasticity, and produces a more uniform, light-textured baked product. It is a white crystalline powder.

Documented risks

Butylated Hydroxyanisole: BHA is classified by the International Agency for Research on Cancer (IARC) as Group 2B (possible human carcinogen) based on studies showing it causes papillomas and squamous cell carcinomas of the forestomach in rats, hamsters, and mice at high doses. A 1983 NTP bioassay confirmed these findings. The National Toxicology Program lists BHA as 'reasonably anticipated to be a human carcinogen' in its Report on Carcinogens. The forestomach is an anatomical structure found in rodents but not humans, creating some uncertainty about direct extrapolation. EFSA's 2012 re-evaluation (EFSA Journal 2012;10(10):2588) concluded that BHA may have endocrine-disrupting potential based on animal data showing interactions with estrogen receptors and androgenic hormone pathways. EFSA found the ADI of 1 mg/kg body weight but noted concerns about endocrine effects. Japan banned BHA for use in foods containing fats and oils, consistent with its generally precautionary approach to synthetic food preservatives. In cosmetics, the EU Scientific Committee on Consumer Safety (SCCS) has assessed BHA and found potential endocrine-disrupting effects at dermal exposure levels. EWG rates BHA as high-concern in Skin Deep cosmetics database. The antioxidant paradox applies: while BHA prevents lipid oxidation in foods, it may paradoxically act as a pro-oxidant in certain biological contexts at certain doses.

Potassium Bromate: Potassium bromate is classified by the International Agency for Research on Cancer (IARC) as Group 2B — a possible human carcinogen — based on sufficient evidence in animals. This classification was formalized in 1999. The landmark toxicology study is Kurokawa et al. (1990), published in Environmental Health Perspectives (PMC1567851), which demonstrated that KBrO3 induces renal cell tumors (kidney cancer), mesotheliomas of the peritoneum, and follicular cell tumors of the thyroid in rats. Importantly, the researchers demonstrated KBrO3 is a complete carcinogen — it possesses both tumor-initiating and tumor-promoting activities for renal tumorigenesis. The mechanism of carcinogenicity involves generation of reactive oxygen species, particularly hydroxyl radicals and superoxide radicals. These radicals cause oxidative DNA damage, specifically 8-hydroxydeoxyguanosine (8-OHdG) formation in rat kidney cells — a well-characterized biomarker of oxidative DNA damage. California declared potassium bromate a known carcinogen under Proposition 65 in 1991, requiring cancer warning labels on California products containing it. Multiple advocacy organizations including CSPI (1999 petition) and EWG (2015 petition) have petitioned the FDA for a federal ban. As of 2025, the FDA has urged voluntary industry elimination since the early 1990s but has not issued a formal ban. Nephrotoxicity from high-dose potassium bromate is well documented in case reports of accidental or intentional poisonings: it causes irreversible renal tubular necrosis, permanent deafness (cochlear damage), and blindness (optic nerve damage). These effects occur at doses far above food consumption scenarios but demonstrate the compound's acute toxicological potency. FDA testing in 1999 found residual potassium bromate above expert-recommended safe limits in more than half of 17 tested bread and roll products, demonstrating that the 'it bakes off completely' argument does not always hold in commercial practice.